On the basis of the above results, we initiated a clinical trial (phase Ia) to define the recommended phase 2 dose (RP2D) and evaluate the efficacy and safety of combined trametinib plus anlotinib therapy in advanced NSCLC patients with non-G12C KRAS mutations. Here, KRAS is linked to non-small cell lung carcinoma.